Background A multicenter phase I/II trial of vinflunine administered in combination with
cisplatin at 80 mg/m 2 was conducted in order to determine the dose-limiting toxicities, the …

Objective Vinflunine (VFL)(Javlor®), a novel fluorinated semisynthetic vinca alkaloid has
shown significant antitumor activity in advanced non-small cell lung cancer (NSCLC). We …

Introduction Vinflunine (Javlor) has shown significant antitumour activity in advanced non-
small cell lung cancer (NSCLC). We propose to define the recommended dose of vinflunine …

7271 Background: VFL (Javlor) is a novel fluorinated semi-synthetic vinca-alkaloid. The
combination of VFL and cisplatin has shown significant antitumour activity in advanced …

A multicentre, single-arm, phase II trial designed to determine the efficacy of single-agent
vinflunine in patients with advanced non-small-cell lung cancer (NSCLC) previously treated …

7110 Background: VFL (Javlor) is a new semi-synthetic vinca alkaloid which has shown
synergistic effects in vitro againts A549 human NSCLC line when combined with CDDP …

Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell
Lung Cancer Previously Treated With Page 1 Phase III Trial Comparing Vinflunine With …

7266 Background: VFL (Javlor) is a novel semi-synthetic vinca-alkaloid that has shown
higher in vivo antitumour activity than vinorelbine in several human tumour models. In …

7511 Background: Vinflunine (VFL) is a new microtubule inhibitor of the vinca alkaloid class
with clinical activity in NSCLC (J. Bennouna, BJC, 2006). Single-agent efficacy and safety of …

Background Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the
intra-venous vinflunine vinca alkaloid microtubule inhibitor have been shown to be effective …